Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
4DMedical Limited (4DX.AX)
AUD3.90
-0.01 (-0.26%)
AU ASX Healthcare Medical - Devices
Address
Melbourne Connect 3053
Carlton, VIC, AU
Carlton, VIC, AU
CEO
Andreas Fouras
Website
4dmedical.com
IPO
2020-08-07
ISIN AU0000095416
Also trades on
Australian Securities Exchange · 4DX.AX (AUD)
Other OTC · FDMDF (USD)
Description
Incorporated in 2012 and headquartered in Carlton, Australia, 4DMedical Limited operates as a medical technology enterprise across Australia and the United States. The company primarily focuses on bringing to market its innovative XV Technology, an advanced system for four-dimensional lung imaging. Beyond this core offering, its suite of products includes a software-as-a-service (SaaS) delivery model, specialized XV lung ventilation analysis software, and Permetium—a preclinical imaging system designed to quantify regional changes in pulmonary function. Additionally, the firm provides the AccuVent 200, a ventilator tailored for small animals.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD3.90
-0.01 (-0.26%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
2.01
Float Shares
442.18M
Free Float %
74.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +18.86% | +9.67% | -1.00% | -0.75% | +132.16% | +1.02% | +1,067.65% | +364.33% | +210.16% | +149.69% | +149.69% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3.90
Ratings Trend (MoM)
33% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | -1 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.18
Grey zone
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+55.9% ★ Q4'25: +259.9% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%-27.3% Q4'25: -638.1% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-906.6% Q4'25: -448.8% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%-822.8% Q4'25: -929.7% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%-78.1% Q4'25: +132.7% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%-34.3% ★ Q4'25: +33.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.09× Q4'25: -0.07× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 2 Rev. Ana. 1 EPS Ana. |
Jun 2027 3 Rev. Ana. 2 EPS Ana. |
Jun 2028 3 Rev. Ana. 3 EPS Ana. |
Jun 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.23M
est: 2.65M (-53.5%)
|
217.0K
est: 4.65M (-95.3%)
|
1.05M
est: 14.50M (-92.7%)
|
718.6K
est: 2.50M (-71.3%)
|
3.75M
est: 4.00M (-6.1%)
|
5.85M
est: 5.90M (-0.8%)
|
7.00M
6.72M – 7.28M
+18.7% YoY
|
29.50M
25.35M – 35.61M
+321.2% YoY
|
60.09M
53.03M – 70.23M
+103.7% YoY
|
90.18M
79.58M – 105.39M
+50.1% YoY
|
| EBITDA |
-14.19M
est: -2.65M (-435.5%)
|
-18.04M
est: -4.65M (-287.9%)
|
-35.25M
est: -14.50M (-143.1%)
|
-33.74M
est: -2.50M (-1,249.8%)
|
-31.86M
est: -4.00M (-696.4%)
|
-45.82M
est: -5.90M (-676.6%)
|
-7.00M
-7.28M – -6.72M
-18.7% YoY
|
-29.50M
-35.61M – -25.35M
-321.2% YoY
|
-60.09M
-70.23M – -53.03M
-103.7% YoY
|
-90.18M
-105.39M – -79.58M
-50.1% YoY
|
| EBIT |
-14.77M
est: -2.65M (-457.5%)
|
-18.78M
est: -4.65M (-303.8%)
|
-36.75M
est: -14.50M (-153.5%)
|
-36.31M
est: -2.50M (-1,352.4%)
|
-35.92M
est: -4.00M (-798.0%)
|
-48.16M
est: -5.90M (-716.3%)
|
-7.00M
-7.28M – -6.72M
-18.7% YoY
|
-29.50M
-35.61M – -25.35M
-321.2% YoY
|
-60.09M
-70.23M – -53.03M
-103.7% YoY
|
-90.18M
-105.39M – -79.58M
-50.1% YoY
|
| Net Income |
-21.98M
est: -9.34M (-135.2%)
|
-21.42M
est: -11.38M (-88.2%)
|
-24.59M
est: -14.18M (-73.5%)
|
-31.46M
est: -31.46M (+0.0%)
|
-35.98M
est: -13.32M (-170.2%)
|
-30.07M
est: -15.98M (-88.2%)
|
-81.39M
-96.04M – -66.73M
-409.3% YoY
|
-13.38M
-13.51M – -13.25M
+83.6% YoY
|
-8.01M
-11.19M – 1.88M
+40.2% YoY
|
365.1K
309.4K – 445.2K
+104.6% YoY
|
| SGA |
4.30M
est: 56.69M (-92.4%)
|
12.70M
est: 99.47M (-87.2%)
|
21.13M
est: 310.18M (-93.2%)
|
13.59M
est: 53.48M (-74.6%)
|
14.95M
est: 85.57M (-82.5%)
|
32.10M
est: 126.21M (-74.6%)
|
149.81M
143.85M – 155.77M
+18.7% YoY
|
630.97M
542.23M – 761.71M
+321.2% YoY
|
1.29B
1.13B – 1.50B
+103.7% YoY
|
1.93B
1.70B – 2.25B
+50.1% YoY
|
| EPS |
-0.08
est: -0.04 (-90.8%)
|
-0.08
est: -0.05 (-54.5%)
|
-0.08
est: -0.07 (-26.5%)
|
-0.10
est: -0.10 (+1.1%)
|
-0.11
est: -0.06 (-77.4%)
|
-0.14
est: -0.07 (-94.4%)
|
-0.37
-0.45 – -0.31
-409.3% YoY
|
-0.06
-0.06 – -0.06
+83.0% YoY
|
-0.03
-0.05 – 0.01
+57.3% YoY
|
0.00
0.00 – 0.00
+106.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-26.36M
OE per share TTM
-0.06
Owner's Yield
-1.34%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
304.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 67 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X HealthTech ETF HEAL | 1.49% | 447.5K | 0.50% |
| 2 | iShares S&P/ASX Small Ordinaries ETF ISO.AX | 0.70% | 610.7K | 0.55% |
| 3 | Vanguard MSCI Australian Small Companies Index ETF VSO.AX | 0.37% | 2.94M | 0.30% |
| 4 | BetaShares - Australian Ex-20 Portfolio Diversifier ETF EX20.AX | 0.21% | 941.9K | 0.25% |
| 5 | BetaShares - Geared Australian Equities Complex ETF GEAR.AX | 0.16% | 700.9K | 0.78% |
| 6 | Xtrackers S&P ASX 200 UCITS ETF 1D XAUS.L | 0.09% | 61.7K | 0.50% |
| 7 | iShares Core S&P/ASX 200 ETF IOZ.AX | 0.07% | 4.67M | 0.05% |
| 8 | BetaShares - Australia 200 ETF A200.AX | 0.07% | 5.23M | 0.04% |
| 9 | BetaShares - Managed Risk Australian Shares Complex ETF AUST.AX | 0.07% | 13.4K | 0.49% |
| 10 | Vanguard Australian Shares Index ETF VAS.AX | 0.07% | 12.42M | 0.07% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-3.3K
Shares Outstanding
592.73M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andreas Fouras | Founder, MD, Chief Executive Officer & Director | 959.1K | — |
| Matt Tucker | Chief Commercial Officer | 585.4K | male |
| Julian Sutton | CFO & Executive Director | 269.2K | male |
| Greg T. Mogel | Chief Medical Officer | — | — |
| Hamish George | Company Secretary | — | male |
| Aidan Jamison | Senior Vice President of Engineering | — | — |
| Rachael Tenkaten | Senior Vice President of Product | — | female |
| Beth Plunkett | Senior Legal Counsel | — | — |
| David Hannes | Senior Vice President of Global Business Development | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4DX.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
